Advanced search
Publication Cover
mAbs Volume 15, 2023 - Issue 1
Submit an article Journal homepage
2,949
Views
2
CrossRef citations to date
0
Altmetric
Report

A HER2-targeted antibody-novel DNA topoisomerase I inhibitor conjugate induces durable adaptive antitumor immunity by activating dendritic cells

Xiaoding Tana Department of Pharmacology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, The People’s Republic of ChinaView further author information
,
Peng Fangb Jiangsu Mabwell Health Pharmaceutical R&D Co. Ltd, Taizhou, Jiangsu Province, The People’s Republic of ChinaView further author information
,
Kaiying Lib Jiangsu Mabwell Health Pharmaceutical R&D Co. Ltd, Taizhou, Jiangsu Province, The People’s Republic of ChinaView further author information
,
Meng Youb Jiangsu Mabwell Health Pharmaceutical R&D Co. Ltd, Taizhou, Jiangsu Province, The People’s Republic of ChinaView further author information
,
Yuxia Caob Jiangsu Mabwell Health Pharmaceutical R&D Co. Ltd, Taizhou, Jiangsu Province, The People’s Republic of ChinaView further author information
,
Hui Xub Jiangsu Mabwell Health Pharmaceutical R&D Co. Ltd, Taizhou, Jiangsu Province, The People’s Republic of ChinaView further author information
,
Xiaohong Zhub Jiangsu Mabwell Health Pharmaceutical R&D Co. Ltd, Taizhou, Jiangsu Province, The People’s Republic of ChinaView further author information
,
Lu Wangb Jiangsu Mabwell Health Pharmaceutical R&D Co. Ltd, Taizhou, Jiangsu Province, The People’s Republic of ChinaView further author information
,
Xin Weib Jiangsu Mabwell Health Pharmaceutical R&D Co. Ltd, Taizhou, Jiangsu Province, The People’s Republic of ChinaView further author information
,
Haiying Wenb Jiangsu Mabwell Health Pharmaceutical R&D Co. Ltd, Taizhou, Jiangsu Province, The People’s Republic of ChinaView further author information
,
Wendi Lib Jiangsu Mabwell Health Pharmaceutical R&D Co. Ltd, Taizhou, Jiangsu Province, The People’s Republic of ChinaView further author information
,
Lei Shib Jiangsu Mabwell Health Pharmaceutical R&D Co. Ltd, Taizhou, Jiangsu Province, The People’s Republic of ChinaView further author information
,
Xiaowei Sunb Jiangsu Mabwell Health Pharmaceutical R&D Co. Ltd, Taizhou, Jiangsu Province, The People’s Republic of ChinaView further author information
,
Dongan Yub Jiangsu Mabwell Health Pharmaceutical R&D Co. Ltd, Taizhou, Jiangsu Province, The People’s Republic of ChinaView further author information
,
Huikai Zhub Jiangsu Mabwell Health Pharmaceutical R&D Co. Ltd, Taizhou, Jiangsu Province, The People’s Republic of ChinaView further author information
,
Zhenzhen Wangb Jiangsu Mabwell Health Pharmaceutical R&D Co. Ltd, Taizhou, Jiangsu Province, The People’s Republic of ChinaView further author information
,
Datao Liub Jiangsu Mabwell Health Pharmaceutical R&D Co. Ltd, Taizhou, Jiangsu Province, The People’s Republic of ChinaView further author information
,
Hui Shenc Department of Clinical Laboratory Medicine, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, The People’s Republic of ChinaView further author information
,
Wei Zhoub Jiangsu Mabwell Health Pharmaceutical R&D Co. Ltd, Taizhou, Jiangsu Province, The People’s Republic of ChinaCorrespondence[email protected]
View further author information
&
Maomao Ana Department of Pharmacology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, The People’s Republic of ChinaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-2872-9074View further author information
ORCID Icon show all
Article: 2220466 | Received 16 Feb 2023, Accepted 29 May 2023, Published online: 14 Jun 2023

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.